Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production.
Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity.
